RxDoctor Payments Data

Melissa Smith, APRN

Family · Riverview, FLNPI 1053393066

Payments from drug & device makers

$10,110in general payments, 2019–2025

Across 584 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$978
  • Lilly USA, LLC$785
  • AstraZeneca$771
  • Pfizer$708
  • Lucid Diagnostics Inc.$627
  • Novo Nordisk$617
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$9,94698%
  • Education$1642%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,110 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$60,465
Medicare patients
281
Services billed
1,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide26$51,646
EliquisApixaban28$44,740
JardianceEmpagliflozin22$36,832
FarxigaDapagliflozin Propanediol23$27,658
MounjaroTirzepatide19$27,065
OzempicSemaglutide20$20,736
MyrbetriqMirabegron12$16,275
Tresiba Flextouch U-200Insulin Degludec12$7,587
Humalog Kwikpen U-100Insulin Lispro17$4,577
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$3,463
Gabapentin83$2,368
Citalopram HbrCitalopram Hydrobromide12$1,984
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,869
Rosuvastatin Calcium107$1,378
Comfort Ez Pen NeedlePen Needle, Diabetic12$1,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$785$78,71045 claims
PfizerEliquis$708$44,74028 claims
Boehringer IngelheimJardiance$231$36,83222 claims
AstraZenecaFarxiga$771$27,65823 claims
Novo NordiskOzempic$617$20,73620 claims
Astellas Pharma US IncMyrbetriq$346$16,27512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.

Other family in Riverview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →